STALLERGENES-GREER
Stallergenes Greer, a biopharmaceutical company specialising in the research, diagnosis and treatment of respiratory allergies, is pleased to announce its strategic direction for the Stallergenes Greer Foundation.
The Stallergenes Greer Foundation, under the aegis of the Fondation de France, aims to build healthier futures for all by focusing on three key areas:
- Advancing scientific research to boost innovation and precision medicine;
- Supporting academic initiatives to further develop future generations of allergy healthcare professionals;
- Engaging in climate action and environmental protection to advance the prevention and treatment of allergies.
The comprehensive approach adopted by the Stallergenes Greer Foundation aims to serve the One Health Initiative that has been formally endorsed by the World Health Organisation (WHO) in particular, and which calls for “the collaborative efforts of multiple disciplines working locally, nationally, and globally to attain optimal health for people, animals and our environment.”
“The strategic direction of the Stallergenes Greer Foundation reflects our unwavering engagement to advance precision medicine and science in the field of allergy for the benefit of society and will contribute to breakthrough collaborations to address complex challenges in allergy and environmental health. I would like to take this opportunity to thank the members of our Scientific Board whose experience and vision are strong assets for the foundation,” stated Michele Antonelli, CEO of Stallergenes Greer and Chairman of the Stallergenes Greer Foundation.
The Stallergenes Greer Foundation will support innovative research projects, encompassing fundamental, applied, environmental and societal research, as well as education.
In 2023, the foundation will allocate up to €150,000 for outstanding work led either by a young scientist or a mid-career scientist to advance precision medicine in the field of allergy, or outstanding work in the environmental field to advance the prevention and treatment of allergies.
The Stallergenes Greer Foundation is governed by a Board of Trustees, which itself brings together a Managing Board and a Scientific Board:
The Managing Board is comprised of Stallergenes Greer senior executives:
- Michele Antonelli, CEO,
- Amer Jaber, EVP Operations Europe,
- Dominique Pezziardi, General Manager France, Belgium and Luxembourg - Global Head of Pricing and Market Access,
- Catherine Kress, Head of Communications and Corporate responsibility.
The Scientific Board is comprised of renowned scientific and medical experts:
- Pascal Demoly, Professor of Pulmonology and Head of Department at the University Hospital, Montpellier (France),
- Alessandro Fiocchi, MD, Director of Allergy at Bambino Gesù Children’s Hospital, Rome, Vatican City (Italy),
- Carla Irani, Associate Professor of Internal Medicine and Clinical Immunology, Allergology - Immunological Asthma at Hôtel Dieu de France University Medical Center, Beirut (Lebanon),
- Kari Nadeau, MD, PhD, Chair of the Department of Environmental Health at the Harvard T.H. Chan School of Public Health (Boston, MA, U.S.A.).
ABOUT STALLERGENES GREER INTERNATIONAL AG
Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of allergies through the research, development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com.
ABOUT FONDATION DE FRANCE
Created in 1969, Fondation de France is a private organisation recognised of public interest, whose mission is to support all forms of generosity in order to translate them into effective actions of general interest. With the 945 foundations it hosts, it supports more than 10,000 promising and innovative initiatives each year, in France and abroad. Independent and private, it operates thanks to the generosity of donors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005514/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coats Completes Acquisition of OrthoLite, Strengthening Footwear Business30.10.2025 08:15:00 CET | Press release
Acquisition aligns with Coats’ Long-Term Growth Strategy in Apparel and Footwear Coats Group plc, a world-leading Tier 2 supplier of critical components to the apparel and footwear industries, announced today that it has completed its acquisition of OrthoLite, a global market leader in footwear materials and the number one brand in premium insoles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030015142/en/ OrthoLite Vietnam The acquisition marks a major milestone in the Company’s long-term growth plans and strengthens its existing footwear division through expansion into the attractive, high-growth premium insole segment. Both companies already have a similar customer base, a complementary global footprint and a commitment to industry-leading innovation and sustainability practices. “OrthoLite is one of the world’s most innovative manufacturers in footwear materials. With our combined capabilities, we’ll now be able to
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year30.10.2025 08:04:00 CET | Press release
First Half Revenue Declined 3.9% at Constant Exchange Rate (CER), -6.9% atActual Exchange Rates (AER),Impacted by Generic Erosion of VYVANSE® and FX HeadwindCore Operating Profit Declined 8.8% at CER in the First Half, Reflecting Revenue Performance and Product Mix; Impact Partially Offset by Operational EfficienciesFirst Half Reported Operating Profit (-27.7% at AER) Impacted by Impairment Losses Incurred in Q2 Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook. Takeda chief executive officer, Christophe Weber, commented: “Takeda’s fiscal year 2025 first half results are consistent with our expectations for core business progress in this year of transition to a new phase focusing on new product launches. Our updated full-year outlook reflects impairment charges associated with strategic pipeline decisions taken in Q2, as well as transactional FX. “Looking ahead, our curr
Aduna, Deutsche Telekom, mBank and Vonage Join Forces at World Banking Forum to Showcase the Future of Banking Security30.10.2025 08:00:00 CET | Press release
This powerful industry collaboration highlights how mobile networks, APIs, and AI can transform banking Vonage, a part of Ericsson (NASDAQ: ERIC), today announced that, together with leaders from Aduna, Deutsche Telekom, and mBank, it is participating in the World Banking Forum in Athens. The event convenes senior banking executives and technology leaders from around the world to advance modern banking through technology innovation and digital transformation. An increase in fraud has emerged from the rise of digital channels in financial services and continues to evolve and grow with new technologies such as AI that enable more sophisticated threats. As cyber threats continue to escalate and regulations tighten, it is more critical than ever for banks to deploy advanced fraud protection strategies. Cybercrime damages are projected to reach $11.9 trillion annually by 2026 and technology innovation is needed to meet regulatory demands and strengthen a financial institution's overall frau
AGCO Power Unveils Next-Generation Sustainable Powertrain Innovations at Agritechnica 202530.10.2025 08:00:00 CET | Press release
At Agritechnica 2025 in Hanover, AGCO Power will unveil a bold vision for the future of agricultural and forestry machinery powertrain solutions—combining cutting-edge diesel technology with pioneering low-carbon innovations designed to meet the evolving needs of farmers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030745855/en/ Juha Heikkilä (left), Manager Electrification, holds NMC battery cells used in the prototype battery, while Kari Aaltonen, Director Engineering, stands beside the concept unit. The battery, designed by AGCO Power, contains a total of 1400 cells and offers 150 kWh of capacity. Highlights include the newest and next‑generation CORE diesel engine family—the 8‑liter, 252 kW CORE80 powering the new 5th‑generation of the Fendt 800 Vario—alongside the AGCO Power CO₂ Calculator concept and a 150 kWh Future Battery Concept developed in‑house by AGCO Power, and cost-effective remanufactured eng
AB InBev Reports Third Quarter 2025 Results30.10.2025 07:05:00 CET | Press release
Consistent execution of our strategy delivered an EBITDA increase of 3.3% with margin expansion and low-single digit Underlying EPS growth Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029571716/en/ Regulated and inside information1 “Driven by the momentum of our megabrands and our innovation in balanced choices and Beyond Beer, our business delivered continued top- and bottom-line growth, even as we navigated a dynamic consumer environment. Given the progress we have made on our deleveraging and solid year-to-date financial results we have announced a new 6 billion USD share buyback program and an interim dividend.” – Michel Doukeris, CEO, AB InBev Revenue +0.9% Revenue increased by 0.9% in 3Q25 with revenue per hl growth of 4.8% and by 1.8% in 9M25 with revenue per hl growth of 4.5%. Reported revenue increased by 0.6% in 3Q25 to 15 133 million USD and d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom